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From the VGF precursor protein originate several low molecular weight peptides,
whose distribution in the brain and blood circulation is not entirely known. Among
the VGF peptides, those containing the N-terminus portion were altered in the
cerebro-spinal fluid (CSF) and hypothalamus of schizophrenia patients. “Hence, we
aimed to better investigate the involvement of the VGF peptides in schizophrenia by
studying their localization in the brain regions relevant for the disease, and revealing
their possible modulations in response to certain neuronal alterations occurring in
schizophrenia”. We produced antibodies against different VGF peptides encompassing
the N-terminus, but also C-terminus-, TLQP-, GGGE- peptide sequences, and the
so named NERP-3 and -4. These antibodies were used to carry out specific ELISA
and immunolocalization studies while mass spectrometry (MS) analysis was also
performed to recognize the intact brain VGF fragments. We used a schizophrenia
rat model, in which alterations in the prepulse inhibition (PPI) of the acoustic startle
response occurred after PCP treatment. In normal rats, all the VGF peptides studied
were distributed in the brain areas examined including hypothalamus, prefrontal
cortex, hippocampus, accumbens and amygdaloid nuclei and also in the plasma.
By liquid chromatography-high resolution mass, we identified different intact VGF
peptide fragments, including those encompassing the N-terminus and the NERPs. PCP
treatment caused behavioral changes that closely mimic schizophrenia, estimated by
us as a disruption of PPI of the acoustic startle response. The PCP treatment also
induced selective changes in the VGF peptide levels within certain brain areas. Indeed,
an increase in VGF C-terminus and TLQP peptides was revealed in the prefrontal cortex
(p < 0.01) where they were localized within parvoalbumin and tyrosine hydroxylase (TH)
containing neurons, respectively. Conversely, in the nucleus accumbens, PCP treatment
produced a down-regulation in the levels of VGF C-terminus-, N-terminus- and GGGE-
peptides (p < 0.01), expressed in GABAergic- (C-terminus/GGGE) and somatostatin-
(N-terminus) neurons. These results confirm that VGF peptides are widely distributed in
the brain and modulated in specific areas involved in schizophrenia.
Keywords: VGF peptides, schizophrenia, brain, nucleus accumbens, prefrontal cortex, phencyclidine, PPI
response
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INTRODUCTION
Schizophrenia is a serious psychiatric illness with an occurrence
of 1% in the world population (Rössler et al., 2005). One
of the main hypotheses about the cause is the glutamatergic
neuronal dysfunction (Carlsson et al., 1997). Indeed, the
treatment of phencyclidine (PCP), which is a non-competitive
N-methyl-D-aspartate (NMDA) receptor antagonist, simulates
certain schizophrenia symptoms (Javitt and Zukin, 1991).
Deficient prepulse inhibition (PPI) of the acoustic startle
responses in schizophrenia patients is due to damage of
sensorimotor pathways. In rats, PPI is damaged by treatments
with different neurotransmitters such as dopamine agonists,
serotonin agonists, or glutamate antagonists other than by
an assortment of different manipulations involving neuronal
pathways within the limbic cortex, ventral and dorsal striatum,
pallidum, and pontine reticular areas (Mouri et al., 2007; Mena
et al., 2016). The vgf (non acronymic) is a neutrophin-induced
gene encoding for a primary product, VGF precursor or pro-
VGF, composed of 617/615 amino acids (rat/mouse and human
respectively) discovered because of a selective up-regulation
by NGF in the rat pheochromocytoma cells (Levi et al.,
1985). Chromosomal mapping has assigned human VGF to
chromosome 7q22 (Canu et al., 1997) and mouse/rat Vgf to
chromosome 5 (Salton et al., 1991). The VGF precursor protein
is widely expressed in the brain and is processed to give rise
to a number of peptides of low molecular weight. Often, the
four N-terminal amino acids (in single letter code) and the
peptide length are used to name the VGF peptides. Several
VGF peptides have been identified as being related to metabolic
mechanisms as is the case of the TLQP-21 peptide belonging
to the TLQP peptide family (Bartolomucci et al., 2006; Brancia
et al., 2010) and the so previously named NERP (neuroendocrine
peptide) family that includes NERP-1, -2 (Yamaguchi et al.,
2007; D’Amato et al., 2012; Melis et al., 2012), -3 (QQET-30;
Fujihara et al., 2012) and -4 (NAPPE-19; D’Amato et al.,
2015). Further functions related to neuronal circuits were also
discovered for certain VGF peptides. Central administrations
of a peptide called AQEE-30 into the hypothalamus, produces
penile erection probably by activating nitric oxide (NO) and
oxytocin (Succu et al., 2004, 2005). Indeed, another peptide
belonging to the TLQP family and called TLQP-62 is involved
in hippocampal neuronal circuits related to psychiatric diseases
(Thakker-Varia et al., 2010), and depression (Thakker-Varia
et al., 2007; Lin et al., 2015). Both TLQP-21 and TLQP-62
seem to be involved in neuronal regulation of the rat oestrus
cycle (Noli et al., 2014) and hamster photoperiodic mechanisms
related to cholinergic neurons of the brain cortex (Noli et al.,
2015). In the Alzheimer’s disease patients, the VGF peptides
named ‘‘GGGE’’ were found decreased in the cerebro-spinal
fluid (CSF; Carrette et al., 2003) while those named PGH,
together with the VGF C-/N- terminus peptides and the NERP-1
were reduced in the brain cortex (Cocco et al., 2010). The
VGF C-/N- terminus peptides have also been related to the
amyotrophic lateral sclerosis mechanisms (Zhao et al., 2008;
Brancia et al., 2016). As to schizophrenia patients, one VGF
N-terminal fragment (VGF24–60) was found to be increased in
the CSF from drug naïve and treated subjects (Huang et al.,
2006, 2007), while in post mortem hypothalamus samples,
immunoreactivity cell density for the VGF N-terminus was
reduced in neurons of the paraventricular and supraoptic
nuclei (Busse et al., 2012). Several loci have been related to
schizophrenia, including the 7q22, but unfortunately, the analysis
of the regional candidate VGF gene, revealed no significant
association to the clinical diagnosis of schizophrenia (Wedenoja
et al., 2010). Although some VGF peptides have crucial roles
in neurodegenerative and neuronal conditions, their localization
in the brain is not completely known. In particular, the
available information regarding VGF peptides and schizophrenia
is limited to the human hypothalamus/CSF and restricted to the
VGF N-terminal fragment with pending information coming
from animal models and other VGF fragments. Therefore,
we aimed to better investigate the involvement of the VGF
peptides in schizophrenia by studying their localization in
specific brain regions, crucial for the disease, and revealing
their possible modulations in response to certain neuron
alterations occurring in schizophrenia. We used a schizophrenia
rat model in which alterations in the PPI of the acoustic
startle response occurred after PCP treatment (Mouri et al.,
2007). Indeed PCP is a glutamate receptor antagonist of the
NMDA subtype, which causes NMDA receptor hypoactivity
(Meador-Woodruff et al., 2003) and mimics both the positive
and negative symptoms of schizophrenia in humans (Slavney
et al., 1977; Allen and Young, 1978; Javitt and Zukin, 1991;
Steinpreis, 1996). Antibodies against sequences encompassing
the C-/N- terminus, TLQP-, and GGGE- peptides, as well as
the so named NERP-3 and -4, were produced and used either
to carry out specific immunosorbent assays (ELISA) or for
immunolocalization studies. High-pressure performance liquid
chromatography-mass spectrometry (HPLC-MS) was also used
to confirm their amino acid sequences. The VGF fragments
to be studied were chosen for their previous involvement in
schizophrenia (N-terminus), other neuronal conditions (GGGE
and C-terminus) or hypothalamic mechanisms (NERPs and
TLQP) that are also altered in many psychiatric diseases
(Oliver et al., 2012; Tognin et al., 2012; Tiwari et al.,
2013).
MATERIALS AND METHODS
Animals
Male Sprague Dawley rats (250–300 g, Envigo Correzzana,
Italy) were assembled four per cage (38 cm × 60 cm × 20 cm).
Rats (n = 88), were taken under precise conditions (24◦C,
60% humidity, reversed 12 h light/dark cycle, with lights
off from 08:00 to 20:00 h), with water and standard food
ad libitum, and then a group (n = 80) were used for the
experiments, performed between 10:00–14:00 h accordingly
to the guidelines of the European Communities Directive
of September 22, 2010 (2010/63/EU) and the Italian
Legislation (D.L. March 4, 2014, n. 26). The protocol has
been approved by the Italian Ministry of Health (Authorization
n.1237/2015-PR to MRM), and by the Ethical Committee
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 June 2017 | Volume 11 | Article 158
Noli et al. VGF Peptides and Schizophrenia
for Animal Experimentation of the University of Cagliari,
Italy.
PCP Treatment and PPI Response
In order to validate the assumption that PCP treatment
was effective in inducing behavioral changes resembling
schizophrenia-like symptoms in our experimental conditions,
i.e., it was effective in modifying PPI, of the acoustic startle
response, 80 male rats were randomly assigned to five
experimental conditions (n = 16/condition), each one with a
different treatment regimen. Within each condition, half of
the rats (n = 8) received PCP (purchased from R&D Systems
Europe Ltd., Abingdon, UK 2.5 mg/kg, SC) or the corresponding
volume of saline (1 mL/kg of rat body weight, SC; n = 8). The
main conditions were as follows: acute treatment (animals were
treated once); sub-chronic treatment (animals were treated once
a day for eight consecutive days); chronic treatment (animals
were treated once a day for 21 consecutive days). The acute
treatment comprised animals that underwent the behavioral
test (PPI assessment) after 10–15 min from the PCP injection.
The sub-chronic and chronic treatment conditions comprised
animals, which underwent the behavioral test (PPI assessment)
30 min after the last PCP injection (no wash out condition)
and animals, which underwent the behavioral test 24 h after
the last PCP injection (wash out condition). Treatments were
carried out between 10:00 h and 13:00 h counterbalancing the
sequence of PCP- and saline- treated rats. The day of the
test, the rats in their home-cages were transferred during the
dark phase of the cycle in a testing room under controlled
environmental conditions (a sound proofed room lit by a dim
red light). Each testing session was conducted with the same
number of PCP treated rats and their matched saline treated
controls. PPI testing was performed with minor modifications
as already described (Frau et al., 2016). The apparatus used
for detection of startle reflexes (Med Associates, St Albans,
VT, USA) consisted of four standard cages placed in sound-
attenuated chambers with fan ventilation. Each cage consisted
of a plexiglas cylinder of 9 cm diameter, mounted on a
piezoelectric accelerometric platform connected to an analog-
digital converter. Two separate speakers conveyed background
noise and acoustic bursts. Both speakers and startle cages
were connected to a main computer, which detected and
analyzed all chamber variables with specific software. Before each
testing session, acoustic stimuli and mechanical responses were
calibrated. The test began after acclimatization phase (5 min),
with a 70 dB background white noise, continuing for the entire
session. This period was followed by three blocks, comprising
five pulse-alone trials of 115 dB (the first and the third), while
the second includes a pseudorandom sequence of 50 trials,
containing 12 pulse-alone trials, 30 trials of pulse preceded by
74, 78, or 82 dB pre-pulses (10 for each pre-pulse loudness level),
and eight no-pulse trials, where exclusively the background noise
was delivered. Time between two consecutive trials (inter-trial
intervals) was arbitrarily selected between 10 s and 15 s. The %
PPI was measured through the formula: % PPI = (100—mean
startle amplitude for prepulse trials/mean startle for pulse alone
trial)× 100.
Statistical Analysis of Behavioral Data
Behavioral data from PPI experiments were analyzed by two
way ANOVA. Although a trend toward a higher inhibition
was observed with increasing tone intensities, we detected no
significant differences in PPI responses to the three different
prepulse intensities, therefore data from the three different
prepulse intensities were put together for each rat to calculate
individual mean values which were used for statistical analyses
conducted by a two way ANOVA with the duration and the
treatment as between subject factors. Post hoc pair wise contrasts
on statistically significant main effects and/or interactions
revealed by ANOVA analysis were obtained through Bonferroni
test. Statistical analyses were applied using PRISM, Graph Pad
5 Software (San Diego, SA, USA) and the significance level were
always p< 0.05.
Tissue Collection
Brain tissues from rats that did not receive any treatment
nor were exposed to the PPI procedure were also used
both for immunohistochemistry (n = 4) as well as for the
determination of amino acid sequence by HPLC-MS (n = 4).
Irrespective of the fact that rats underwent or not the PPI
procedure and/or the PCP treatment, for ELISA at sacrifice, rats
underwent deep diethyl ether anesthesia, blood (approximately
2 ml) was drawn by cardiac puncture, hence rats were rapidly
decapitated for tissue extraction. The brain slide samples
(coronal sections of 2 mm) were obtained using a cooled rat
brain matrix through razor blades. The samples from different
brain areas (hypothalamus, ventral and dorsal hippocampus,
amigdaloid and accumbens nuclei, prefrontal cortex) were
dissected from the brain slides using punches of 3, 4 and
5 mm dimensions as appropriate, following the coordinates
of the Paxinos Atlas of the rat brain (Paxinos and Watson,
2007). Tissue samples were extracted (∼10 ml/g wet tissue)
in ice-cold phosphate buffer saline (PBS: 0.01 mol/L, pH 7.4)
containing protease inhibitor cocktail (PIC, 5 m/ml in PO4
buffer, 0.01–0.05 M, pH 7.2–7.4 + NaCl 0.15 MP8340, Sigma-
Aldrich, Schnelldorf, Germany), homogenized for 3 min using
a micro sample pestle, hence tubes were heated for 10 min,
and centrifuged (3000 rpm, 15 min). Supernatants were stored
frozen until use (−30◦C). Blood samples were collected in a
tube containing ethylenediaminetetraacetic (EDTA: 1.78mg/ml),
rapidly centrifuged (11,000 rpm, 5 min), and plasma was
stored frozen (−30◦C) until analysis. For HPLC-ESI-MS, brain
samples pooled from four untreated male rats were extracted
in PBS containing PIC, homogenized by an Ultra-Turrax
Homogenizer (Ika-Werke, Staufen, Germany), heated in a
boiling water bath (10–15 min), and centrifuged (3000 rpm,
10–15 min). The supernatant was transferred on centrifugal
filters with the molecular weight cut-off of 10 kDa and
3 kDa (Amicon Ultra device, Merck Millipore, Tullagreen
Carrigtwohill Co. Cork, Ireland) and the resulting filtrate was
lyophilized and stored frozen. Differently from ELISA and
HPLC-MS, for immunohistochemistry, rats were anesthetized
using chloral hydrate (400 mg/kg i.p.) and perfused-fixed
with 4% paraformaldehyde in 0.1 M phosphate buffer, pH
7.2–7.4.
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VGF Antisera
The VGF N- and C- terminus, TLQP, NERP-3 and NERP-4 (also
named NAPPE) antisera were produced as previously reported
(Ferri et al., 1995; Brancia et al., 2005; Cocco et al., 2010; D’Amato
et al., 2015), while in order to obtain the VGF375–407 antiserum,
the N-terminal decapeptide (GGGEDEVGEE), was conjugated
with bovine thyroglobulin, via an additional C-terminal cysteine
and used for immunizations. Specificity of each antiserum was
achieved through ELISA (Table 1). It is relevant to point out
here that our VGF antibodies, raised against truncated sequences
at their N- or C- terminus, are expected to cross-react also
with extended peptides. We assume that TLQP-62 will react in
the TLQP assay much as TLQP-21 and in a way comparable
to the VGF C-terminus standard in the relevant assay. Such
assumption appears to fit well with our previous studies of
TLQP-peptides, based on gel chromatography coupled with
ELISA (Brancia et al., 2010, 2016; Noli et al., 2014, 2015). In
some tissues, a large MW form bona fide corresponding to VGF
(found in the void volume upon sephadex chromatography)
was recognized by both the VGF N-terminus and C-terminus
assays (Brancia et al., 2010; Cocco et al., 2010; Noli et al.,
2014).
ELISA
Competitive ELISA was performed as previously reported
(D’Amato et al., 2008; Cocco et al., 2010). For each assay
characterization (Table 1), a standard curve was obtained
using a range of concentrations of each of the peptides listed.
The peptide corresponding to the immunogen was treated as
‘‘reference’’, with a certain amount of such peptide producing
a 50% inhibition of the maximum signal (50% inhibitory
concentration), and showing 100% reactivity in the assay. The
other peptides listed resulted in a standard curve parallel to the
‘‘reference’’ one, but variably shifted to the right (more peptide
required to produce 50% inhibition, hence lower reactivity in
the assay, i.e., <100% reactivity), or to the left (less peptide
produced 50% inhibition, hence higher reactivity, >100% vs.
reference peptide). Synthetic peptides were used for plate coating
(Nunc, Milan, Italy) for 3 h at room temperature, then the
wells were treated with PBS (containing 9% normal serum
from the secondary antibody donor species, 20 nM aprotinin,
and 1 mg/mL EDTA) for 2 h. Primary incubations, with
the VGF antibodies, (dilution: 1:5000–1:12000) were carried
out in duplicate, including serial standard dilutions in parallel
with rat samples (brain or plasma; 3 h at room temperature).
Biotinylated secondary antibodies (1:10000; Jackson, West
Grove, PA, USA), streptavidin-peroxidase conjugate (Biospa,
Milan, Italy), and tetramethylbenzidine (X-tra Kem-En-Tec,
Taastrup, Denmank) as substrate were used to reveal the
positive labeling. The reaction was stopped with hydrogen
cloride (1 mol/L) and optical density was measured at 450 nm
using a multilabel plate reader (Chameleon: Hidex, Turku,
Finland). Recovery of synthetic peptide/s added to plasma,
or to tissue samples at extraction was >85% for all assays
used.
Statistical Analysis of ELISA Data
Analysis of variance of ELISA data was carried out by
one-way ANOVA, followed by post hoc multiple comparison
tests (Student-Newman-Keul test), or by two-tailed
Student’s t-test as appropriate by means of the StatistiXL
software.
TABLE 1 | VGF assay characterization.
Antisera Peptide IC50 pmol/ml CV1 % CV2 % Cross-reactivity %
rVGF C-term. rVGF609–617 (IEHVLLHRP)1 0.02 2–3 8–10 100
hVGF607–615 <0.01
hVGF603–612 <0.01
TLQP rVGF556–564 (TLQPPASSR)2 1.1 3–5 10–13 100
rVGF555–564 R-TLQPPASSR∗ 3.5
rVGF556–566 (TLQP-11) 122
rVGF556–576 (TLQP-21) 183
rVGF N-term. rVGF24–31 (APPGRSDVYP)3 10 3–7 9–12 100
hVGF23–30 <0.001
mVGF24–31 <0.001
NERP-4 rVGF489–497 (NAPPEPVPP)4 6 5 6–9 100
rVGF489–507 95
rVGF488–496 <0.001
NERP-3 rVGF197–206 (LESPGPERVW)5 10 8 5–8 100
rVGF197–207 <0.001
hVGF177–206 90
hVGF199–206 98
GGGE rVGF375–382 (GGGEDEVG)6 0.6 3 8–10 100
hVGF373–380 <0.001
rVGF375–420 150
IC50: concentration of peptide producing 50% inhibition of the maximum signal; CV1 and CV2: intra- and inter-assay variation, respectively; h: human; r: rat. 1–6“reference”
peptides, used for immunization, plate coating, and as measurement standards, respectively. ∗Arg-extended: an Arginine residue was added at the peptide N-terminus,
to mimic its extended sequence within the VGF precursor. The cross-reactivity of each peptide was expressed compared to the “reference” peptide used in the assay,
hence a >100% reactivity is indicated for peptides with higher reactivity (e.g., TLQP-21).
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HPLC High-Resolution ESI-MS and MS/MS
Analysis
Freeze-dried material (5 µg) were re-suspended in 50 µl of
aqueous formic acid (0.1% v/v) and 10 µl of the solution
analyzed by an Ultimate 3000 RSLCnano system coupled with an
Orbitrap Elite mass spectrometer (ThermoFisher, San Jose, CA,
USA), using an EASY-Spray Column PepMaprRSLCC18 (3µm
particle diameter; 75 µm ID × 15 cm). Eluent solutions were
constituted by: 0.1% (v/v) aqueous formic acid and acetonitrile
with 0.1% (v/v) aqueous formic acid. The used gradient was
linear from 0% to 55% of B in 35 min, at a flow rate of
300 nL/min. The Elite-Orbitrap mass spectrometer operated
in data-dependent mode. Each full MS scan (60,000 resolving
power) was followed by fiveMS/MS scans applied on the first five
multiple-charged ions dynamically selected and disintegrated
through collision-induced dissociation at a normalized collision
energy of 35%. Thermo Proteome Discoverer 1.4 software was
utilized to analyze Tandem mass spectra, while the SEQUEST
cluster (University of Washington, Seattle, WA, USA, licensed
by Thermo Electron Corp) was useful to search engine against
UniProtKB Rattus norvegicus proteome (release 2016-03). The
limits used for peptide matching were Xcorr scores greater than
1.5 for singly charged peptide ions while 2.0 for doubly charged
ions and 2.5 for triply charged ions. Precursor mass search
tolerance was set to 10 ppm, and fragment mass tolerance to
0.02 Da. The N-terminal modification (Gln→ pyro-Glu) and the
C-terminal amidation were selected as dynamic modifications.
A false discovery rate (FDR) below 1% was applied. Peptide
sequences and sites of covalent modifications were confirmed
by manual spectra annotation by matching experimental MS/MS
spectra with the theoretical ones generated by the MS-Product
program available on Protein Prospector website1. The match
was assumed as positive when: (1) all the experimental m/z
values were higher than 5% in the theoretical fragmentation
spectrum; and (2) experimental and theoretical values differed
less than±0.03 m/z.
Immunohistochemistry
After fixation time, brains were included in an embedding
medium (Cocco et al., 2003) and cut (at 10 µm) using a HM-560
cryomicrotome (Microm; Walldorf, Germany; Ferri et al., 2002).
Sections comprehensive of the prefrontal cortex and the nucleus
accumbens were incubated overnight in a humid chamber
mixing the anti VGF antibodies (dilutions: 1:600–1:4000)
with different neurotransmitters/enzymes/neuromodulators
(Table 2), all diluted in PBS containing 30ml/L of normal donkey
serum, 30 ml/l of normal rat serum and 0.02 g/L NaN3. Relevant
species-specific donkey secondary antibodies conjugated with
Cy3 or Cy2 (Jackson Immunoresearch Laboratories, West
Grove, PA, USA) were used (1:400). Slides were covered
with PBS-glycerol (40%), observed and photographed using
BX41 and BX51 fluorescence microscopes (Olympus, Milan,
Italy) equipped with the Fuji S2 and S3 Pro digital cameras
(Fujifilm, Milan, Italy). Routine controls included substitution
of each antibody, in turn, with PBS, the use of pre-immune or
1http://us.expasy.org/tools
TABLE 2 | Antibodies used in immunohistochemistry.
Antigen Diluition Species Producer/Reference
Calretinin 1:5000 Mouse Millipore
r.GAD 1:1500 Mouse DSHM
r.NOS 1:600 Sheep Chemicon
h.NOS 1:800 Rabbit Biomol international
NPY 1:700 Rabbit Ferri et al. (1988)
r/h Parvoalbumin 1:10000 Mouse Sigma
Somatostatin 1:800 Rabbit Abcam
r/h TH 1:1000 Mouse Sigma
r. TH 1:1000 Chicken Millipore
r. VAChT 1:2000 Goat ENZO
GAD, glutamic acid decarboxylase; NOS, nitric oxide synthase; NPY, neuropeptide
Y; TH, tyrosine hydroxylase; VAChT, vesicular acetylcholine transporter; r, rat;
h, human.
non-immune sera, and the testing of each secondary antibody
with their respective non-relevant primary antibodies.
RESULTS
VGF Peptide Levels in Normal Rats
In the normal rats, the VGF peptides were expressed in all the
brain areas examined (hypothalamus, prefrontal cortex, nucleus
accumbens, dorsal and ventral hippocampus, amygdaloid
nucleus) and also in the plasma (Figure 1). VGF peptide levels
ranged between approximately 4 pmol/g and 900 pmol/g in the
brain and between 6 pmol/ml and 40 pmol/ml in plasma. Among
the brain areas studied, the richest in the VGF peptides was
the amygdaloid nucleus containing about 900 pmol/g, revealed
with the N-terminus antibody. Analysis of each brain area
for the content of the VGF peptides, revealed the following:
the hypothalamus, dorsal hippocampus and prefrontal cortex
contained more NERP-4, the accumbens and amygdaloid nuclei
were more reactive to the N-terminus antibody, while the ventral
hippocampus contained more TLQP peptides compared to the
other VGF peptides. Conversely, in plasma, the TLQP peptides
were the most represented.
HPLC-MS Analysis of VGF Peptides
The RP-HPLC high-resolution ESI-MS analysis allowed the
detection of 13 mass values attributed to different fragments
of proVGF. Table 3 reports the experimental monoisotopic
m/z values of the mono-charged peptides of proVGF, the
post-translational modifications and the sequences determined
by MS/MS experiments. Fragments VGF24–54 and VGF24–60
derived from the proVGF N-terminus, and fragments
VGF587–600, VGF588–600, derived from the C-terminus portion.
Moreover, the following peptides belonging to the NERP family
were identified: NERP-3 (VGF180–209), with the N-terminal
Gln converted to Pyro-Glu, NERP1 (VGF285–309), amidated
at the C-terminus and two fragments encompassing NERP-4
(VGF489–507 and VGF487–507). We unfortunately failed to
identify the TLQP and GGGE peptides, however, we detected
and characterized the same VGF353–372 fragment previously
identified in the striatum (Karlsson et al., 2013), and its shorter
form (VGF360–372).
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FIGURE 1 | Content of the VGF peptides in the brain and plasma of male rats. VGF peptides were measured, by ELISA, in extracts from selected brain areas
(hypothalamus, dorsal and ventral hippocampus, prefrontal cortex, nucleus accumbens and amygdaloid nucleus). Mean values (SEM) are from eight rats/tissue.
Pmol/g: picomoles/grams.
Effect of Acute, Sub-Chronic or Chronic
PCP Treatment on the PPI Response
As shown in Figure 2, PCP treatment induced an impairment
of PPI response after acute, sub-chronic and chronic treatment,
with some differences in the entity of the effects due to the
duration of the treatment regimen. Accordingly, two ways
ANOVA revealed a significant effect of the drug (F(1,110) = 107.2,
p< 0.001), of the treatment regimen (F(4,110) = 17.92, p< 0.001),
and of interaction between the two factors (F(4,110) = 24.46,
p< 0.001). Post hoc comparisons revealed that acute, sub-chronic
and chronic PCP treatments without wash out, all induced PPI
impairment (24.33%,−2.62% and−1.60% for acute, sub-chronic
and chronic treatment, respectively, compared to values between
57.68% and 66.49% of saline treated rats, all p < 0.001); in
contrast, PCP-treated animals which underwent the 24 h wash
out displayed PPI values indistinguishable from those of their
saline matched controls (64.07% and 63.51% for sub-chronically
and chronically PCP treated rats, respectively; all p > 0.05 when
comparing PCP-washed out animals to the corresponding saline-
treated rats, and all p < 0.001 when comparing PCP-washed
out animals with the corresponding PCP not washed out
rats). Finally, post hoc comparisons revealed also a significant
difference in the entity of PPI impairment between acutely
(24.33%) and both no wash out sub-chronically (−2.62%)
and chronically (−1.60%) PCP-treated rats (both p < 0.001),
with no difference in the entity of PPI impairment between
no washed out sub-chronically and chronically treated rats
(p> 0.05).
TABLE 3 | m/z values ([M+H]+, monoisotopic) of VGF peptides detected in rat brain by RP-high-pressure performance liquid chromatography (HPLC) high-resolution ESI
mass spectrometry (MS) and confirmed by MS/MS experiments.
Position Experimental [M+H]+ Modifications Sequences
24–54 3242.58 (± 0.03) – APPGRSDVYPPPLGSEHNGQVAEDAVSRPKD
24–60 3868.88 (± 0.04) – APPGRSDVYPPPLGSEHNGQVAEDAVSRPKDDSVPEV
180–209 3390.67 (± 0.03) N-Term (Q→pyro D) QQETAAAETETRTHTLTRVNLESPGPERVW
238–282 4836.47 (± 0.05) – MSENVPLPETHQFGEGVSSPKTHLGETLTPLSKAYQSLSAPFPKV
285–309 2558.31 (± 0.03) C-Term (Amidated) LEGSFLGGSEAGERLLQQGLAQVEA
301–329 3150.61 (± 0.04) C-Term (Amidated) QQGLAQVEAGRRQAEATRQAAAQEERLAD
353–372 2461.08 (± 0.03) – GLQETQQERENEREEEAEQE
360–372 1391.55 (± 0.03) – ENEREEEAEQE
487–507 2171.21 (± 0.03) – KKNAPPEPVPPPRAAPAPTHV
489–507 1915.02 (± 0.03) – NAPPEPVPPPRAAPAPTHV
587–600 1700.83 (± 0.03) – RAQEEADAEERRLQ
588–600 1544.73 (± 0.03) – AQEEADAEERRLQ
Numbering refers to the sequence of the protein with the signal peptide.
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FIGURE 2 | Effect of acute, subchronic or chronic PCP (phencyclidine)
treatment on prepulse inhibition (PPI) response. Rats were treated once a day
as well as once a day for 8 or 21 days with PCP (2.5 mg/kg, SC) or saline
(1 mL/kg, SC) and tested for the PPI of the acoustic startle response 30 min
or 24 h after the last drug treatment. AC, acute treatment; SNW and SW,
subchronic treatment without or with 24 h wash out, respectively; CNW and
CW, chronic treatment without or with 24 h wash out, respectively. Mean
values (SEM) from 8 rats/group. ∗∗∗p < 0.001 vs. the corresponding saline
treated rats; ###p < 0.001 vs. acutely (1 day) treated rats; §§§p < 0.001 vs. the
corresponding no washed out rats (two way ANOVA followed by Bonferroni’s
post hoc comparisons).
VGF Peptide Levels in Saline- and PCP-
Treated Rats
VGF peptide levels were measured in the prefrontal cortex,
nucleus accumbens, dorsal and ventral hippocampus,
amygdaloid nucleus and hypothalamus as well as in plasma
of saline- and PCP- treated rats that underwent the PPI test
under the acute, sub-acute and chronic treatment condition,
with the aim of unraveling possible changes in the levels of
one or more VGF peptides (Figure 3). We found changes in
the content of VGF peptides exclusively within the prefrontal
cortex and nucleus accumbens but not in the other brain areas
studied or in plasma (not shown). In the prefrontal cortex,
we found an increase in VGF C-terminus after sub-chronic
and chronic PCP-treated rats, as well as for TLQP peptides
exclusively in the sub-chronic group when compared to the
respective saline treated rats (p < 0.01). Conversely, in the
nucleus accumbens, PCP treatment produced a decrease in VGF
C-terminus levels after all types of treatment (acute, sub-chronic
and chronic), while N-terminus- and GGGE-peptides were
reduced after chronic PCP treatment when compared to the
respective groups of saline-treated rats (p < 0.01). In both
the prefrontal cortex and nucleus accumbens, the amount of
all peptides changed after PCP-treatment, returned to similar
levels to those of saline-treated controls after 1 day from
the last PCP treatment (sub-chronic and chronic wash out
groups).
VGF Peptide Localization in Brain
The localizations of the VGF peptides, whose levels were changed
by ELISA in the prefrontal cortex and nucleus accumbens after
PCP treatment, were studied in the same areas of normal rats, to
characterize the neuronal circuits containing the VGF peptides.
We used VGF antibodies together with antibodies against
the relevant neurotransmitters, enzymes or neuromodulators
(Table 2). In the prefrontal cortex, the ∼57% of the VGF
C-terminus immunoreactivity (Figure 4A) was found within
the majority of parvoalbumin perikarya (Figure 4B), while the
remained positive labeling stayed uncharacterized. The majority
of the TLQP immunoreactivity (Figure 4C) was found in
axons containing tyrosine hydroxylase (TH; Figure 4D) while
roughly half of the TH positive nerve axons contained the
TLQP peptides. In the nucleus accumbens, GGGE- (not shown)
and VGF C-terminus- (Figures 4E,F) immunoreactivities
were revealed in ∼30%–40% of neuron terminals containing
glutamic acid decarboxylase (GAD; and vice-versa) inside
the shell. The N-terminus immunoreactivity was almost
wholly found in all structures containing somatostatin (axons,
perikarya and nerve terminals; Figures 4G,H) and in a small
percentage (∼5%) of NO synthase (NOS) containing cells (not
shown).
DISCUSSION
Ample studies demonstrate that fragments derived from
the VGF precursor have important neuronal functions or
have been found in the CSF from neurological patients.
In contrast, there is limited data regarding the expression
and localization of the VGF-derived peptides in the brain
(van den Pol et al., 1994). We have provided here the
first evidence that rat brain is rich in fragments containing
different portions of the proVGF sequence, and certain peptides
are widely distributed at high levels in those brain areas
with a key role in neuronal disorders, i.e., the prefrontal
cortex, nucleus accumbens, hippocampus, hypothalamus and
amygdaloid nucleus. Our results show that PCP treatment, which
causes behavioral changes that closely mimic schizophrenia,
estimated by us as a disruption of PPI in PCP-treated rats,
induces also changes of VGF peptide levels in the prefrontal
cortex and nucleus accumbens. Pertinent to this study is
that the prefrontal cortex controls the activity of the nucleus
accumbens (Mogenson et al., 1980; Grace et al., 2007). When we
investigated the specific phenotype of the neurons containing the
VGF peptides whose levels were changed after PCP treatment,
we identified parvoalbumin- and TH- neurons (containing
the VGF C-terminus and TLQP-peptides, respectively) within
the prefrontal cortex, and GAD-, (containing the VGF C-
terminus- and the GGGE-peptides), somatostatin- and NOS-
neurons (containing the VGF N-terminus) in the nucleus
accumbens. All these neurotransmitters and/or neuropeptides
have a role in PCP related mechanisms. Indeed, it is noteworthy
that PCP treatment induces not only behavioral changes,
such as those that can be detected by assessing PPI, but
also neuropathological changes, including changes related
to dopaminergic and serotoninergic neurotransmissions, and
reduction of parvoalbumin expression in the hippocampus and
frontal cortex (Cochran et al., 2003; Reynolds et al., 2004;
Abdul-Monim et al., 2006). GABA interneurons (in particular
those containing parvoalbumin) of the prefrontal cortex are
halted in PCP-treated animals (Mouri et al., 2007), with the
consequence of disinhibiting (i.e., exciting) pyramidal neurons
(see Moghaddam and Javitt, 2012). Somatostatin perfusion into
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FIGURE 3 | Effect of PCP treatment on the content of VGF peptides in the prefrontal cortex and nucleus accumbens. In the prefrontal cortex, we found an increase
in VGF C-terminus levels after sub-chronic and chronic PCP treatment, as well as in TLQP peptides exclusively after sub-chronic PCP treatment when compared to
the respective saline treated rats (p < 0.01). Conversely, in the nucleus accumbens, PCP treatment produced a decrease in the VGF C-terminus levels after all types
of treatments (acute, sub-chronic and chronic), while N-terminus- and CGGE-peptide levels were reduced after chronic PCP treatment when compared to the
respective groups of saline-treated rats (p < 0.01). The levels of all VGF peptides changed in PCP- (sub-chronic and chronic) treated rats returned to similar levels to
those of saline-treated controls after 1 day from the last PCP treatment (sub-chronic and chronic wash out groups). Mean values are (SEM) from eight rats/group.
∗p < 0.01 vs. the corresponding saline-treated rats (one way ANOVA followed by Bonferroni’s post hoc comparisons). Pmol/g: picomoles/grams.
the nucleus accumbens increases dopamine release in the same
area, possibly via the glutamatergic system, through AMPA
and NMDA receptors, or by inhibiting the GABA release
(Ikeda et al., 2012). Disturbances in the parvoalbumin and
somatostatin activity have been commonly reported in the
prefrontal cortex from subjects with schizophrenia (Hashimoto
et al., 2003; Mellios et al., 2009; Morris et al., 2009; Fung et al.,
2010; Curley et al., 2011; Volk et al., 2012). Interestingly, we
found that VGF peptides containing the N-terminus portion
are decreased after PCP treatment in the nucleus accumbens,
where we identified by MS analysis, the same N-terminal
fragment (VGF24–60) previously found increased in the CSF
from schizophrenia patients (Huang et al., 2006). These results
highly suggest an involvement of the VGF N-terminal peptides
in the alterations of the activity of the neuronal systems at the
basis of schizophrenia. Regarding the GGGE peptides, previously
identified and found reduced in the CSF from Alzheimer’s
patients (Carrette et al., 2003), we revealed their presence
in all the brain areas studied with a selective alteration in
the prefrontal cortex after PCP treatment, suggesting their
involvement in schizophrenia as well as Alzheimer mechanisms.
Unfortunately, in this study, we failed to detect, by MS analysis,
peptides containing the TLQP and GGGE sequences probably
due to the low intensity of their ions. TLQP peptides were
first identified in the rat brain (Trani et al., 2002) but despite
their role in neuronal circuits (Thakker-Varia et al., 2007,
2010; Lin et al., 2014), they have never been identified by
MS analysis, suggesting particular adversities to reveal them
with this technique. However, the high levels of these peptides
revealed by ELISA in the hypothalamus and hippocampus are
in line with their known bioactivity in these areas (Hahm
et al., 1999, 2002; Jethwa and Ebling, 2008). The role of
the VGF peptides in neurons containing TH, parvoalbumin,
GAD and somatostatin remains to be investigated; however
the major hypothesized role is that VGF peptides could act as
neuromodulators. The VGF role as neuromodulator has already
been reported for certain VGF peptides, for instance NERPs
regulate vasopressin secretion (Toshinai and Nakazato, 2009;
D’Amato et al., 2012), TLQP-21 increases FSH release from the
pituitary (Aguilar et al., 2013), TLQP-62 regulates hippocampal
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FIGURE 4 | Phenotype of the VGF positive neurons. Prefrontal cortex. Using the VGF C-terminus (A) and the parvoalbumin (B) antibodies, an incomplete
colocalization profile was found in the cell bodies, with some perikarya labeled by the VGF C-terminus antibody only (identified by the arrows, A). Almost all the TLQP
positive nerve axons (C) contained also tyrosine hydroxylase (TH; D, identified by the arrows). Nucleus accumbens. C-terminus-immunoreactivity (E) was revealed in
a subpopulation of neuron terminals containing glutamic acid decarboxylase (GAD; F) inside specific areas of the shell (identified by the circles). The N-terminus
immunoreactivity (G) was almost completely found in all axons-, perikarya- and nerve terminals-secreting somatostatin (H). VGF antibody: Cy3 red labeling,
parvoalbumin, somatostatin, GAD: Cy2 green labeling. Magnification: 600× (A–D,G,H) and 400× (E,F).
synaptic activity (Thakker-Varia et al., 2007, 2010; Bozdagi et al.,
2008; Lin et al., 2015).
Regarding the significance of the specific VGF peptide
changes we observed in the prefrontal cortex and nucleus
accumbens, we attempt to make some speculations. In the
prefrontal cortex, we found an increase in both VGF C-terminus
and TLQP peptides after PCP treatment. Since at least in the
hippocampus, the TLQP-62 enhances synaptic plasticity (Alder
et al., 2003), we suggest that the parallel increase in the VGF
C-terminus peptide/s (probably including the VGF precursor), as
well as TLQP peptides, might be relevant for potentiating and/or
increasing synaptic transmission. Our hypothesis would fit well
with those studies showing a general increase in dendritic spine
density after chronic PCP treatment in the rat prefrontal cortex
(Flores et al., 2007). Hence, our VGF peptides could be one of the
proteins involved in this process, as for instance the synapsin-
1, which, involved in the neurotransmitter release at synapses,
has been proved similarly up-regulated in the prefrontal cortex
after PCP treatment (Pickering et al., 2013). As to the nucleus
accumbens, GGGE and VGF C-/N- terminus levels were
decreased after PCP treatment. All these peptides were reduced
as a consequence of neurodegeneration in Alzheimer’s disease
(Carrette et al., 2003; Cocco et al., 2010). In view of the significant
reduction in the gray matter density observed in the nucleus
accumbens after sub-chronic PCP treatment (Barnes et al., 2015),
such findings may indicate a degree of neuronal degeneration
in such area. In conclusion, increasing attention has been given
recently to several neurotransmitters, in view of their role in
schizophrenia related mechanisms. Since the prefrontal cortex
and nucleus accumbens contain different neurotransmitters, it is
important to investigate how they interact as a novel approach
for the treatment of schizophrenia. The changes in the content of
specific VGF peptides after PCP treatment found in this study,
may suggest a role for these peptides acting as neuromodulators
on the release of neurotransmitters crucial for neuropathology
of schizophrenia, which may have a potential importance for
therapeutic approaches. Future studies are needed to uncertain
the VGF peptide roles in schizophrenia.
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